LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
166
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ormat Technologies, Inc. To Contact The Firm

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ormat Technologies, Inc. (“Ormat” or the “Company”) (NYSE: ORA ) of the August 10, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Ormat stock or options between August 8, 2017 and May 15, 2018 and would like to discuss your legal rights, click here : www.faruqilaw.com/ORA.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26 th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the District of Nevada on behalf of all those who purchased Ormat securities between August 8, 2017 and May 15, 2018 (the “Class Period”).  The case, Costas v. Ormat Technologies, Inc., et al , No. 3:18-cv-00271 was filed on June 11, 2018 and has been assigned to Judge Robert Clive Jones.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) there were errors in the income tax provision relating to Ormat’s valuation allowance based on its ability to utilize foreign tax credits in the U.S. prior to their expiration; (2) Ormat netted certain deferred income tax assets and deferred income tax liabilities across different tax jurisdictions that are not permitted to be netted pursuant to generally accepted accounting principles; (3) Ormat’s internal controls over financial reporting were ineffective; (4) this forced the Company to restate its second, third, and fourth quarter 2017 financial statements; and (5) consequently, Ormat’s statements about its business, operations, and prospects were materially false and misleading.

On May 11, 2018, Ormat announced that it was delaying the filing of its Quarterly Report for the period ended March 31, 2018 with the United States Securities and Exchange Commission (“SEC”) because management had failed to identify an error with its financial statement presentation, which impacted the Company’s balance sheets over previous reporting periods.

On this news, Ormat’s share price fell from $56.35 per share on May 10, 2018 to a closing price of $52.77 on May 14, 2018—a $3.58 or a 6.35% drop over two trading days.

On May 16, 2018, Ormat announced that it would restate its second, third, and fourth quarter 2017 financial statements and its full-year 2017 financial statements and warned investors not to rely upon the Company’s previously issued financial statements.

On this news, Ormat’s share price fell from $53.02 per share on May 15, 2018 to a closing price of $52.35 on May 16, 2018—a $0.67 or a 1.26% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ormat’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Rate and Betterment's Mortgage Play: Savings or Spin?

Updated Category News Views 151

So here’s the scoop: Rate just teamed up with Betterment on February 17, 2026, offering some pretty slick mortgage incentives for those sitting on at least $100K in their investment accounts. But let’s dig into the nitty-gritty before you start dreaming of that low-rate home loan. Betterment's Strategy: Solid Gains or Hype? The partnership aims to deliver discounted...

Continue Reading
UK Water Companies Gain Confidence After Regulatory Update

Updated Category News Views 253

Morgan Stanley Highlights UK Water Sector Improvements Investment risks surrounding listed UK water companies have significantly decreased following a key regulatory decision concerning water bill increases in England and Wales. According to analysts from Morgan Stanley, this development has created a more favorable landscape for investors in the sector. Key Insights From...

Continue Reading
SiLC Technologies Unveils Advanced Eyeonic Trace Scanner

Updated Category News Views 228

SiLC Technologies Introduces Eyeonic Trace Laser Line Scanner SiLC Technologies, a leader in the development of advanced integrated FMCW LiDAR solutions, recently announced an exciting new product: the Eyeonic Trace Laser Line Scanner. This state-of-the-art Class 1 Laser Line Scanner is engineered to achieve precise measurements of objects from distances of up to 10...

Continue Reading
Accord BioPharma Launches HERCESSI™ for Cancer Treatment

Updated Category News Views 94

Accord BioPharma Announces FDA Approval for HERCESSI™ Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has achieved a major milestone in cancer treatment with the FDA's approval of a new 420mg strength of HERCESSI™ (trastuzumab-strf). This biosimilar to Herceptin (trastuzumab) targets different types of HER2-overexpressing cancers, such as...

Continue Reading
Why Oklo Stock is Soaring This Week and What to Expect

Updated Category News Views 493

What’s Driving Oklo Inc’s Stock Surge? Oklo Inc (NYSE: OKLO) is making waves in the stock market as its shares witness impressive growth. Over the past month, the company has experienced a remarkable rally of approximately 60%. Investors are keen to learn about the driving forces behind this upward trend. Recent Positive Developments This recent surge can primarily be...

Continue Reading